Ensituximab（Cat No.:I042230）is a monoclonal antibody that targets the tumor-associated antigen Sialyl-Tn (STn), which is overexpressed in many types of cancer, including colorectal, breast, and gastric cancers. By binding to STn, ensituximab is designed to inhibit tumor growth and promote immune-mediated destruction of cancer cells. It is being investigated in clinical trials as a potential treatment for solid tumors, particularly in combination with other therapies. Early studies are focusing on its safety, tolerability, and efficacy in targeting cancers that express the STn antigen.
